| Literature DB >> 31085172 |
Milica Momcilovic1, David B Shackelford2.
Abstract
In this issue of Cancer Cell, Elgendy et al. describe the use of intermittent fasting as a strategy to reduce tumor glucose levels and sensitize otherwise resistant tumor cells to metformin. The authors demonstrate that intermittent fasting before metformin treatment sensitized tumors to metformin and significantly reduced tumor growth.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31085172 DOI: 10.1016/j.ccell.2019.04.008
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743